EVLO Stock Overview A clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Evelo Biosciences, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Evelo Biosciences Historical stock prices Current Share Price US$0.0005 52 Week High US$0.07 52 Week Low US$0.0001 Beta 1.56 1 Month Change 0% 3 Month Change 11.11% 1 Year Change -98.96% 3 Year Change -100.00% 5 Year Change -100.00% Change since IPO -100.00%
Recent News & Updates
Evelo Biosciences, Inc. Files Form 15 Jan 27
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index Dec 14 Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index
Evelo Biosciences Provides Non-Compliance Update Dec 04
Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis Oct 18 Evelo Biosciences, Inc. announced that it has received $25.468522 million in funding from FMR LLC, Flagship Pioneering Jul 13
See more updates
Evelo Biosciences, Inc. Files Form 15 Jan 27
Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index Dec 14 Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index
Evelo Biosciences Provides Non-Compliance Update Dec 04
Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis Oct 18 Evelo Biosciences, Inc. announced that it has received $25.468522 million in funding from FMR LLC, Flagship Pioneering Jul 13
Evelo Biosciences, Inc. Announces Management Changes Jul 12
Evelo Biosciences, Inc. Announces Management Changes Jul 11
Evelo Biosciences Announces Reverse Stock Split to Meet the Minimum Per Share Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market Jun 30
Evelo Biosciences, Inc. Eliminates Position of Jonathan Zung, Chief Development Officer Feb 18
David R. Epstein Intends to Resign from Evelo Biosciences, Inc.'s Board Feb 11
Evelo Biosciences, Inc. Announces Executive Changes Feb 03 Evelo Biosciences, Inc. Announces Updates to its Clinical Pipeline
Price target decreased to US$8.00 Nov 19
High number of new directors Nov 16
Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way? Aug 18 Evelo Biosciences, Inc. Plans to Replace President Simba Gill
Evelo Biosciences, Inc. Announces Two Phase 2 Clinical Read-Outs with EDP1815 in Atopic Dermatitis Expected in First quarter and Second Quarter 2023; Phase 2 Data for EDP2939 in Psoriasis expected in Second Half 2023 Aug 12
Evelo Biosciences GAAP EPS of -$0.40 beats by $0.03 Aug 11
Evelo Biosciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 06
Evelo Biosciences, Inc. Appoints Marella Thorell as the Chief Financial Officer Effective from September 1, 2022 Jul 19
Marella Thorell is the new finance chief of Evelo Biosciences Jul 18 Evelo Biosciences, Inc.(NasdaqGS:EVLO) dropped from Russell 2000 Dynamic Index
Evelo Biosciences: Hope After Dilution? Jun 06
Evelo Biosciences, Inc. Announces Executive Changes Jun 02
High number of new directors Jun 01
High number of new directors May 02
Price target decreased to US$15.40 Apr 27
David P. Perry Not Stand for Re-Election to Board of Directors of Evelo Biosciences, Inc Apr 27
Evelo Biosciences, Inc. Plans to Meet with Health Authorities to Discuss the Path Forward to Registration Trials for EDP1815 in Patients with Psoriasis Apr 15
Price target increased to US$22.50 Apr 11
Evelo Biosciences, Inc. Announces Executive Appointments Apr 06
Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry? Mar 21
Evelo Biosciences, Inc. Announces Data from Post-Treatment Follow-Up (Part B) of its Phase 2 Trial of EDP1815 in Mild and Moderate Psoriasis Mar 01
Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis Feb 18
Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in Edp1815 Phase 2 Psoriasis Trial Feb 08
Price target increased to US$23.70 Feb 02
Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases Jan 18
Evelo Biosciences, Inc. Announces Updates of Phase 2 Clinical Trial of EDP1815 in Atopic Dermatitis and Phase 1B Clinical Data with EDP1815 in Atopic Dermatitis Dec 23
High number of new directors Nov 02
High number of new directors Oct 02
Evelo Biosciences, Inc. Announces Positive Data from Its Phase 2 Study Evaluating EDP1815 Versus Placebo for the Treatment of Mild and Moderate Psoriasis Sep 27
Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load? Sep 25
Price target increased to US$23.33 Jun 30
Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-Inflammatory Product Candidate Edp2939 at the American Association of Immunologists Meeting May 14
What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry? Mar 11
Evelo Biosciences, Inc. to Report Q4, 2020 Results on Mar 09, 2021 Mar 03
Appoints John A. Hohneker, M.D. to Board of Directors Feb 18 Evelo Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $67.5 million.
Evelo Bio secures ~$67.5M capital raise Jan 29
New 90-day high: US$18.60 Jan 29 Evelo Biosciences, Inc. Updates Data Following Completion of the Mild and Moderate Atopic Dermatitis Cohort in Its Phase 1B Clinical Trial
New 90-day high: US$13.89 Jan 13
Evelo Biosciences Expands Clinical Programs Jan 09
Evelo Biosciences expands EDP1815 mid-stage trial to atopic dermatitis Jan 07
New 90-day high: US$12.28 Dec 28
Evelo Biosciences, Inc. Appoints Jonathan Zung as Chief Development Officer Dec 23
Evelo Biosciences, Inc. Enters into Development and Clinical Master Services Agreement with Halo Pharmaceutical, Inc Dec 20
Evelo Biosciences, Inc. Updates on Its Clinical Trails Dec 18
Independent Chairman recently bought US$51k worth of stock Dec 15
Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares Dec 15
Evelo Biosciences, Inc. Reports Positive Topline Clinical Data in Phase 1b Trial of EDP1815 in Atopic Dermatitis Dec 11
Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares? Dec 11
Price target raised to US$9.67 Dec 10
New 90-day high: US$6.41 Dec 10
Evelo Biosciences identifies new lead oncology candidate Dec 09
Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis Dec 04
Evelo Bio's EDP1815 completes enrollment targeting interim data in mid-stage psoriasis study Dec 03
Price target lowered to US$9.00 Nov 12
Evelo Biosciences, Inc. Announces Preclinical Data for EDP1908 Nov 10
Evelo Biosciences EPS beats by $0.04 Oct 29
Evelo Biosciences, Inc. Completes Enrollment in Phase 1b Clinical Trial Cohort Evaluating EDP1815 in Atopic Dermatitis Oct 15
Evelo Biosciences Treats First Patients in Phase 2 Dose-Ranging Trial of EDP1815 for the Treatment of Psoriasis Oct 14
New 90-day high - US$5.20 Aug 19
Evelo Biosciences, Inc. to Report Q2, 2020 Results on Jul 30, 2020 Jul 24
Evelo Biosciences, Inc.(NasdaqGS:EVLO) dropped from Russell Microcap Value Index Jul 03 Shareholder Returns EVLO US Biotechs US Market 7D 0% -4.8% -0.5% 1Y -99.0% -3.2% 21.1%
See full shareholder returns
Return vs Industry: EVLO underperformed the US Biotechs industry which returned -3% over the past year.
Return vs Market: EVLO underperformed the US Market which returned 23.1% over the past year.
Price Volatility Is EVLO's price volatile compared to industry and market? EVLO volatility EVLO Average Weekly Movement n/a Biotechs Industry Average Movement 11.3% Market Average Movement 5.9% 10% most volatile stocks in US Market 18.2% 10% least volatile stocks in US Market 3.0%
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine EVLO's volatility change over the past year.
About the Company Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology.
Show more Evelo Biosciences, Inc. Fundamentals Summary How do Evelo Biosciences's earnings and revenue compare to its market cap? EVLO fundamental statistics Market cap US$9.49k Earnings (TTM ) -US$82.35m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) EVLO income statement (TTM ) Revenue US$0 Cost of Revenue US$0 Gross Profit US$0 Other Expenses US$82.35m Earnings -US$82.35m
Last Reported Earnings
Sep 30, 2023
Earnings per share (EPS) -4.34 Gross Margin 0.00% Net Profit Margin 0.00% Debt/Equity Ratio -127.1%
How did EVLO perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/13 05:56 End of Day Share Price 2025/02/11 00:00 Earnings 2023/09/30 Annual Earnings 2022/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Evelo Biosciences, Inc. is covered by 12 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Matthew Luchini BMO Capital Markets Equity Research Gary Nachman BMO Capital Markets Equity Research Clarence Powell BMO Capital Markets Equity Research
Show 9 more analysts 
